ORIC Pharmaceuticals, Inc. (ORIC)
| Market Cap | 1.37B +43.3% |
| Revenue (ttm) | n/a |
| Net Income | -140.35M |
| EPS | -1.35 |
| Shares Out | 103.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 217,109 |
| Open | 13.59 |
| Previous Close | 13.74 |
| Day's Range | 13.30 - 13.93 |
| 52-Week Range | 7.23 - 14.93 |
| Beta | 0.97 |
| Analysts | Strong Buy |
| Price Target | 20.67 (+56.24%) |
| Earnings Date | Aug 3, 2026 |
About ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutat... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for ORIC stock is "Strong Buy." The 12-month stock price target is $20.67, which is an increase of 56.24% from the latest price.
News
Oric Pharmaceuticals price target raised to $27 from $25 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $27 from $25 and keeps a Buy rating on the shares post the Q2 report.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address m...
Oric Pharmaceuticals reports Q2 EPS (38c), consensus (36c)
“The recent initiation of Himalayas-1, a global Phase 3 registrational trial, brings us closer to delivering a potentially practice-changing therapy for patients with prostate cancer,” said Jacob M. C...
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamid...
ORIC Pharmaceuticals Earnings release: Q2 2026
ORIC Pharmaceuticals released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
ORIC Pharmaceuticals Quarterly report: Q2 2026
ORIC Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 3, 2026.
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalaya...
Oric Pharmaceuticals initiates Himalayas-1 trial
Oric Pharmaceuticals (ORIC) announced the initiation of the Himalayas-1 global Phase 3 registrational trial in patients with metastatic castration-resistant prostate cancer previously treated with abi...
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamid...
Oric Pharmaceuticals resumed with a Buy at Stifel
Stifel analyst Laura Prendergast resumed coverage of Oric Pharmaceuticals (ORIC) with a Buy rating and $14 price target A Phase 3 trial for lead asset rinzimetostat is expected to initiate…
ORIC Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The conference highlighted imminent initiation of a 600-patient phase III prostate cancer study, with a finalized protocol and dose, and emphasized rinzimetostat's competitive efficacy and superior safety profile. The EGFR program demonstrated strong CNS activity and best-in-class potential, while robust cash reserves support clinical plans into 2028.
ORIC Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
Two late-stage oncology programs are advancing, with rinzimetostat set for imminent phase III launch in prostate cancer and enasertib data expected in the second half of 2024. Rinzimetostat shows strong safety differentiation versus competitors, and regulatory clearance has been secured for its pivotal trial.
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address m...
Oric Pharmaceuticals moved to Buy rating at Goldman Sachs
Goldman Sachs moved Oric Pharmaceuticals (ORIC) to a Buy rating and $15 price target from its Early Stage Biotech designation. The company’s clinical data which demonstrated a “potentially differentia...
ORIC Pharmaceuticals Slides: Company presentation
ORIC Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Oric Pharmaceuticals price target lowered to $16 from $17 at Citi
Citi lowered the firm’s price target on Oric Pharmaceuticals (ORIC) to $16 from $17 and keeps a Buy rating on the shares.
Oric Pharmaceuticals reports Q1 EPS (34c), consensus (32c)
“The first quarter marked a pivotal step for ORIC as we selected our Phase 3 dose for rinzimetostat, reported data supporting a potential best-in-disease profile, and moved toward the initiation…
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026
ORIC Pharmaceuticals Earnings release: Q1 2026
ORIC Pharmaceuticals released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.
ORIC Pharmaceuticals Quarterly report: Q1 2026
ORIC Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 4, 2026.
ORIC Pharmaceuticals Proxy statement: Proxy filing
ORIC Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
ORIC Pharmaceuticals Proxy statement: Proxy filing
ORIC Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Oric Pharmaceuticals presents Rinzimetostat preclinical data at AACR
ORIC Pharmaceuticals (ORIC) “announced the presentation of multiple poster presentations at the 2026 American Association for Cancer Research Annual Meeting highlighting the potential of rinzimetostat...
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC). The investigation focuses on O...